Brand-name drugs make up just 10 percent of prescriptions filled in the United States, but account for 72 percent of drug spending.
Drugs that are under patent are the true source of high American drug costs.
The FDA has found that drug prices decline to 55 percent of the brand-name price when two generic manufacturers begin making a product.
As long as we’re going to have patented drugs, letting drug manufacturers set their own prices will remain a key driver of America’s higher drug spending.
(the above is some excerpts stitched together to provide a taste; you should really read the whole thing) First of all, thanks to Ms.
I would kind of like to complain about Vox calling Epi Pen a “red herring” when they were the ones who brought it up, but I think the problem is deeper than that.
Discussing generic drug costs is completely different from discussing brand name drug costs, and the two issues have very different arguments around them.
I find that such a policy will lead to a decline in industry R&D by between 23.4% and 32.7%.
This prediction, however, is accompanied by several caveats.” 8.Epi Pen is, in a way, a bit of a red herring […] Harvoni, a [patented] pill that cures Hepatitis C, costs ,114 here — and ,554 in the United Kingdom.Less red tape around generic drug competition wouldn’t really change that fact.In fact, about 90 percent of drugs prescribed in the country right now are generic.Brand name drugs are the reason that America has higher per-capita drug spending than other countries.Kliff and Vox for responding to me; it’s always neat to get featured in real news sources as if I were a real writer or something instead of just a guy with a blog.